Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 billion), missing the consensus of 71.89 billion Danish kroner.
週三，諾和諾德(Novo Nordisk A/S)（紐交所：NVO）報告了2024年第三季度銷售額爲711.11億丹麥克朗（約103億美元），低於共識的718.9億丹麥克朗。
The global sales increased 21% year over year (up 23% at constant currency), driven by increased sales across the portfolio.
全球銷售額同比增長21%（按不變的貨幣計算爲23%），主要受產品組合銷售增加的推動。
GLP-1 diabetes sales increased by 15% at CER to 34.94 billion Danish kroner, and Obesity care sales increased by 55% at CER to 18.80 billion Danish kroner.
GLP-1糖尿病銷售額按CER計算增長15%，達到349.4億丹麥克朗，肥胖護理銷售額按CER計算增長55%，達到188億丹麥克朗。
Also Read: Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
還閱讀：Wegovy製造商簽署數百萬交易，用於每月肥胖藥物。
Insulin sales increased by 10% at CER to 12.51 billion Danish kroner, and rare disease sales increased by 17% at CER to 4.57 billion Danish kroner.
胰島素銷售額按CER計算增長10%，達到125.1億丹麥克朗，罕見疾病銷售額按CER計算增長17%，達到45.7億丹麥克朗。
The company reported GAAP EPS of 6.12 Danish kroner, beating the consensus of 6.02 Danish kroner.
公司報告的按照GAAP計算的每股收益爲6.12丹麥克朗，超過了6.02丹麥克朗的共識。
Wegovy sales reached 17.30 billion Danish kroner, up 81% and Ozempic sales increased 26% at constant currency to 29.80 billion Danish kroner.
Wegovy銷售額達到173億丹麥克朗，增長了81%，而Ozempic銷售額按固定匯率增長26%，達到298億丹麥克朗。
Lars Fruergaard Jørgensen, president and CEO, said, "The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before."
總裁兼首席執行官Lars Fruergaard Jørgensen表示：「銷售增長主要受到我們基於GLP-1的糖尿病和肥胖治療需求增加的推動，我們爲比以往更多的患者提供服務。」
Operating profit increased to 33.8 billion Danish kroner, with margin expanding from 45.8% to 47.4%.
營業利潤增至338億丹麥克朗，利潤率從45.8%擴大至47.4%。
"Novo Nordisk is the market leader with 53.9% measured by total monthly prescriptions and 50.0% measured by new-to-brand prescriptions," the company said.
諾和諾德是市場領導者，通過總月度處方量和新品種處方量分別佔53.9%和50.0%，公司表示。
Guidance: Novo Nordisk expects 2024 sales growth of 23%-27% on a constant exchange rate basis compared with previous estimates of 22%-28%.
指引：諾和諾德預計2024年銷售額將在恒定匯率基礎上增長23%-27%，較之前的預估22%-28%有所提升。
The company tightened its operating profit growth guidance to 21%-27%, compared to the previously expected 20%-28%.
公司將其營業利潤增長指引調整至21%-27%，與先前預期的20%-28%相比略有提升。
"Following higher-than-expected volume growth in recent years, including GLP-1-based products such as Ozempic and Wegovy, combined with the expectation of continued volume growth and capacity limitations at some manufacturing sites, the outlook also reflects expected continued periodic supply constraints and related drug shortage notifications across a number of products and geographies," it added.
「受益於近年來成交量增長超出預期，包括Ozempic和Wegovy等基於GLP-1的產品，以及預期持續增長和一些製造地點的產能限制，展望也反映了預計持續的週期性供應約束以及相關產品和地理位置藥物短缺通知，」它補充道。
Novo Nordisk said it is investing in internal and external capacity to increase supply in the short and long term.
諾和諾德表示正在投資內部和外部能力，以在短期和長期內增加供應。
Price Action: NVO stock is down 2.90% at $106.94 at the last check on Wednesday.
價格走勢：NVO股票在上週三最後一次檢查時下跌2.90%，報106.94美元。
- Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
- 基因治療開發商beam therapeutics報告早期鐮狀細胞性貧血試驗中有一名患者死亡。
Photo by Tobias Arhelger via Shutterstock
圖片由shutterstock提供
譯文內容由第三人軟體翻譯。
